Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain tumor biobank aims to unlock secrets of rare genetic mutation

NCT ID NCT07242963

Knowledge-focused Sponsor: Mohammad H. Abu Arja Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 02, 2026 · Updated 2 times

Summary

This study is building a biobank of blood, tissue, and health information from 300 children and adults with relapsed or hard-to-treat sonic hedgehog medulloblastoma, a type of brain tumor. Researchers want to learn more about a specific genetic mutation called U1, which may affect how the tumor grows and responds to treatment. Participants will not receive direct treatment, but their samples could help develop better therapies in the future.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help researchers design better treatments for relapsed SHH medulloblastoma by understanding the U1 mutation.
What could go wrong
This is an observational registry, not a treatment trial. It will not directly benefit participants and may not lead to new therapies for years.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Dec 2035

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Group 1 - Patients diagnosed/treated at Texas Children's Hospital (TCH) or one of the participating registry institutions. Group 2 - Patients diagnosed at non-registry institutions (an institution not participating in the registry as a site with IRB approval with BCM/TCH as the coordinating center). Group 3 - Biological parents of patients in Group 1 or 2.

Ages

3 to 50 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: For Groups 1 and 2, subjects are eligible to be included in the study only if all of the following criteria are met: * Age Patients must be ≥ 3 and ≤ 50 years of age at the time of initial diagnosis. * Diagnosis Participants must have a diagnosis of SHH medulloblastoma by histologic or molecular criteria at the time of original diagnosis or relapse. * Disease status The disease must be recurrent, refractory, or progressive following therapy, including radiotherapy and chemotherapy. * Available tumor tissue sample for U1 testing Participants must have available tumor tissue samples to be tested for the U1 mutation. For Group 3, biological parent(s) of a subject participating in Group 1 or 2 are eligible. Exclusion Criteria: Subjects not meeting the inclusion criteria will be excluded.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Medulloblastoma recurrent are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

childhood medulloblastoma medulloblastoma medulloblastoma SHH activated medulloblastoma SHH activated and TP53 mutant medulloblastoma SHH activated and TP53 wild-type Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Medulloblastoma recurrent Medulloblastoma, childhood, recurrent Medulloblastoma, SHH-activated and TP53 mutant Medulloblastoma, SHH-activated and TP53 wildtype

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Baylor College of Medicine

    RECRUITING

    Houston, Texas, 77004, United States

  • MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.